跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BAVENCIO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BAVENCIO
Authorized
STANDARD
BAVENCIO
emd serono, a division of emd inc., canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
337eb7d842f68160
Company
emd serono, a division of emd inc., canada
Type
Standard
Approval Details
Approval Id
337eb7d842f68160
Drug Approval Canada Name
BAVENCIO
Product Name
BAVENCIO
Status
Marketed
Status Date
2017-12-18
Original Market Date
2017-12-18
Din
02469723
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FF04 AVELUMAB
Atc Name
l 01 ff 04
Aig Number
0159690001
Company Name
emd serono, a division of emd inc., canada
Company Address
2695 North Sheridan Way, Suite 200, Mississauga, Ontario, Canada, L5K 2N6
Active Ingredients
AVELUMAB
20 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
337eb7d842f68160
Type
Standard
Back to Health Canada Approvals